S6K2 promises an important therapeutic potential for cancer

S6K2, the newer member of S6 Kinase family, is a crucial modulator of Akt/mTOR signaling pathway and is a member of AGC kinase family that regulates cellular growth and survival. S6K1 and S6K2 share high sequence similarity; therefore, S6K2 had been underestimated. However, recent studies displayed...

Full description

Saved in:
Bibliographic Details
Published in:Future oncology (London, England) England), 2019-01, Vol.15 (1), p.95-102
Main Authors: Sever, Nurettin lter, Cengiz ahin, Sevilay
Format: Article
Language:English
Subjects:
Amino acids
Apoptosis
Breast cancer
cancer cell survival
cancer therapy
Cell adhesion & migration
Cell cycle
Cell division
Cell growth
Gene amplification
Gene expression
Kinases
Localization
Lung cancer
Medical prognosis
Phosphorylation
Protein synthesis
Proteins
Roles
S6 kinase 2
Studies
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:S6K2, the newer member of S6 Kinase family, is a crucial modulator of Akt/mTOR signaling pathway and is a member of AGC kinase family that regulates cellular growth and survival. S6K1 and S6K2 share high sequence similarity; therefore, S6K2 had been underestimated. However, recent studies displayed distinct functions of S6K2. Activated by both Akt/mTOR and Ras/Raf/Mek/Erk signaling pathways, S6K2 regulates cancer cell survival via different routes. Complexation with antiapoptotic proteins BRAF and PKC avoids non-small-cell lung cancer cells from apoptosis upon FGF-2 stimulation. Indirect upregulation of the translation of antiapoptotic proteins Bcl-XL and XIAP in HEK293T cells and interference with TNF-induced apoptosis in MCF-7 cells are other routes of cancer cell survival. The aforementioned studies on S6K2 necessitate the development of therapies targeting only on S6K2. Studies targeting S6K2 may help to build important roads for cancer therapy.
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2018-0332